The Immunology and Immunotherapy for COVID-19

Overview

Journal Expert Rev Mol Med

Specialty General Medicine

Date 2021 Dec 17

PMID 34915958

Citations 2

Authors

Yixin Liu

Xinsheng Zhou

Xuan Liu

Xiaotao Jiang

Affiliations

Soon will be listed here.

Abstract

The ongoing global pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and significantly impacts the world economy and daily life. Symptoms of COVID-19 range from asymptomatic to fever, dyspnoea, acute respiratory distress and multiple organ failure. Critical cases often occur in the elderly and patients with pre-existing conditions. By binding to the angiotensin-converting enzyme 2 receptor, SARS-CoV-2 can enter and replicate in the host cell, exerting a cytotoxic effect and causing local and systemic inflammation. Currently, there is no specific treatment for COVID-19, and immunotherapy has consistently attracted attention because of its essential role in boosting host immunity to the virus and reducing overwhelming inflammation. In this review, we summarise the immunopathogenic features of COVID-19 and highlight recent advances in immunotherapy to illuminate ideas for the development of new potential therapies.

Citing Articles

Vascular Alterations Following COVID-19 Infection: A Comprehensive Literature Review.

Karakasis P, Nasoufidou A, Sagris M, Fragakis N, Tsioufis K Life (Basel). 2024; 14(5).

PMID: 38792566 PMC: 11122535. DOI: 10.3390/life14050545.

Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review.

Tirelli C, De Amici M, Albrici C, Mira S, Nalesso G, Re B Biology (Basel). 2023; 12(2).

PMID: 36829456 PMC: 9953200. DOI: 10.3390/biology12020177.

References

Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View

Ali S, Uddin S, Ali A, Anjum F, Ali R, Shalim E . Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma. Immunotherapy. 2021; 13(5):397-407. PMC: 7871744. DOI: 10.2217/imt-2020-0263. View

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

Wruck W, Adjaye J . SARS-CoV-2 receptor ACE2 is co-expressed with genes related to transmembrane serine proteases, viral entry, immunity and cellular stress. Sci Rep. 2020; 10(1):21415. PMC: 7723043. DOI: 10.1038/s41598-020-78402-2. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Wang W, Liu X, Wu S, Chen S, Li Y, Nong L . Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics. J Infect Dis. 2020; 222(9):1444-1451. PMC: 7337810. DOI: 10.1093/infdis/jiaa387. View

Chen Y, Zhu L, Huang W, Tong X, Wu H, Tao Y . Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. Emerg Microbes Infect. 2021; 10(1):1390-1403. PMC: 8274519. DOI: 10.1080/22221751.2021.1942227. View

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

10.

Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M . Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin Transl Med. 2021; 11(2):e297. PMC: 7839959. DOI: 10.1002/ctm2.297. View

11.

Van Gool A, Kruit W, Engels F, Stoter G, Bannink M, Eggermont A . Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci. 2003; 25(1):11-20. DOI: 10.1023/a:1022449613907. View

12.

Zhang H, Rostami M, Leopold P, Mezey J, OBeirne S, Strulovici-Barel Y . Expression of the SARS-CoV-2 Receptor in the Human Airway Epithelium. Am J Respir Crit Care Med. 2020; 202(2):219-229. PMC: 7365377. DOI: 10.1164/rccm.202003-0541OC. View

13.

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

14.

Sa Ribero M, Jouvenet N, Dreux M, Nisole S . Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020; 16(7):e1008737. PMC: 7390284. DOI: 10.1371/journal.ppat.1008737. View

15.

Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L . Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis. 2020; 221(11):1762-1769. PMC: 7184346. DOI: 10.1093/infdis/jiaa150. View

16.

Hung I, Lung K, Tso E, Liu R, Chung T, Chu M . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238):1695-1704. PMC: 7211500. DOI: 10.1016/S0140-6736(20)31042-4. View

17.

Cantuti-Castelvetri L, Ojha R, Pedro L, Djannatian M, Franz J, Kuivanen S . Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020; 370(6518):856-860. PMC: 7857391. DOI: 10.1126/science.abd2985. View

18.

de Candia P, Prattichizzo F, Garavelli S, La Grotta R, De Rosa A, Pontarelli A . Effect of time and titer in convalescent plasma therapy for COVID-19. iScience. 2021; 24(8):102898. PMC: 8297982. DOI: 10.1016/j.isci.2021.102898. View

19.

Lippi G, Plebani M . Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020; 58(7):1131-1134. DOI: 10.1515/cclm-2020-0198. View

20.

Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S . [Management of COVID-19: the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(2):147-157. PMC: 8800711. DOI: 10.3785/j.issn.1008-9292.2020.02.02. View